Literature DB >> 15853440

The WHO World Alliance for Patient Safety: a new challenge or an old one neglected?

I Ralph Edwards1.   

Abstract

The WHO World Alliance on Patient Safety is a new, all encompassing project to improve medical care. Individual patients are the focus and all countries are encouraged to develop systems in which medical error, therapeutic accidents and failures are minimised. The potential for adverse events is present at all levels of healthcare and in all disciplines. One working group in the Alliance is charged with promoting and developing a 'reporting and learning' culture for adverse events in all areas of medical care. Central to current thinking for this group is a no-fault approach and to report near misses. The aim is not to provide certainty over the individual events, but rather to draw attention to possible improvements in systems that may prevent future problems. Adverse events relating to drug therapy have been reported for decades to national pharmacovigilance authorities, but this is aimed at finding problems with the drugs themselves as early as possible. The Alliance approach in the area of drug safety, by contrast, has a greater focus on safety in the systems of drug provision (including prescription and dispensing) and other systematic issues relating to safe drug provision, such as fraudulent drugs. Thus, current pharmacovigilance can be seen as representing a part of the reporting and learning envisaged by the Alliance. The two approaches are also complementary, but there are practical and philosophical areas of overlap in which difficulties may occur, such as anonymised reporting in a no-fault system and consequent impossibility for follow-up. In pharmacovigilance follow-up for more information is regarded as essential. Whether pharmacovigilance broadens into the area of patient safety or the latter involves completely new systems to do its work will be a matter for each country to consider. One thing is certain, working together both systems will improve patient care, but without cooperation more bureaucracy will take valuable health professional time with a lesser result.

Entities:  

Mesh:

Year:  2005        PMID: 15853440     DOI: 10.2165/00002018-200528050-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  15 in total

1.  The Erice declaration: on communicating drug safety information.

Authors: 
Journal:  Prescrire Int       Date:  1998-12

2.  Reducing errors in medicine.

Authors:  D M Berwick; L L Leape
Journal:  Qual Health Care       Date:  1999-09

3.  Adverse events in British hospitals: preliminary retrospective record review.

Authors:  C Vincent; G Neale; M Woloshynowych
Journal:  BMJ       Date:  2001-03-03

4.  [Incidence of adverse events in hospitals. A retrospective study of medical records].

Authors:  T Schiøler; H Lipczak; B L Pedersen; T S Mogensen; K B Bech; A Stockmarr; A R Svenning; A Frølich
Journal:  Ugeskr Laeger       Date:  2001-09-24

5.  Labelling and 'Dear Doctor' letters: are they noncommittal?

Authors:  A C Kees van Grootheest; I Ralph Edwards
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Adverse events in New Zealand public hospitals I: occurrence and impact.

Authors:  Peter Davis; Roy Lay-Yee; Robin Briant; Wasan Ali; Alastair Scott; Stephan Schug
Journal:  N Z Med J       Date:  2002-12-13

7.  Tachycardia during cisapride treatment.

Authors:  S Olsson; I R Edwards
Journal:  BMJ       Date:  1992-09-26

8.  The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II.

Authors:  L L Leape; T A Brennan; N Laird; A G Lawthers; A R Localio; B A Barnes; L Hebert; J P Newhouse; P C Weiler; H Hiatt
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

9.  The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada.

Authors:  G Ross Baker; Peter G Norton; Virginia Flintoft; Régis Blais; Adalsteinn Brown; Jafna Cox; Ed Etchells; William A Ghali; Philip Hébert; Sumit R Majumdar; Maeve O'Beirne; Luz Palacios-Derflingher; Robert J Reid; Sam Sheps; Robyn Tamblyn
Journal:  CMAJ       Date:  2004-05-25       Impact factor: 8.262

10.  Adverse events in New Zealand public hospitals II: preventability and clinical context.

Authors:  Peter Davis; Roy Lay-Yee; Robin Briant; Wasan Ali; Alastair Scott; Stephan Schug
Journal:  N Z Med J       Date:  2003-10-10
View more
  11 in total

1.  Pharmacovigilance is... Vigilance.

Authors:  I Ralph Edwards; Rachida Soulayamani Bencheikh
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

2.  The Erice declaration : the critical role of communication in drug safety.

Authors:  Bruce Hugman
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Poisons centres and the reporting of adverse drug events: the case for further development.

Authors:  Glyn N Volans; Lakshman Karalliedde; Heather M Wiseman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  The future of pharmacovigilance: a personal view.

Authors:  I Ralph Edwards
Journal:  Eur J Clin Pharmacol       Date:  2008-01-03       Impact factor: 2.953

5.  Adverse drug effects and their clinical management: a personal view.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

6.  Consumer medication management and error.

Authors:  Denys T Lau
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

7.  The knowledge, attitude and behaviours of nurses about pharmacovigilance, adverse drug reaction and adverse event reporting in a state hospital.

Authors:  Fisun Vural; Seval Ciftci; Birol Vural
Journal:  North Clin Istanb       Date:  2015-01-24

8.  Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff.

Authors:  Fabiana Rossi Varallo; Cleopatra S Planeta; Patricia de Carvalho Mastroianni
Journal:  Clinics (Sao Paulo)       Date:  2017-01-01       Impact factor: 2.365

9.  Civil liability of the ophthalmologist in the São Paulo Court of Appeals.

Authors:  Isabel de Fátima Alvim Braga; Kelly de Oliveira Vieira; Thiago Gonçalves Dos Santos Martins
Journal:  Einstein (Sao Paulo)       Date:  2017

10.  Use of a text message-based pharmacovigilance tool in Cambodia: pilot study.

Authors:  Sophie Baron; Flavie Goutard; Kunthy Nguon; Arnaud Tarantola
Journal:  J Med Internet Res       Date:  2013-04-16       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.